Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F De Man

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Journal of the American Heart Association|February 1, 2018
Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting StentsLiefke C van der Heijden, Marlies M Kok, Paolo Zocca, et al.
JAMA Cardiology|January 24, 2017
Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical TrialClemens von Birgelen, Liefke C van der Heijden, Mounir W Z Basalus, et al.
JACC. Cardiovascular Interventions|March 8, 2016
Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS TrialsMarlies M Kok, Liefke C van der Heijden, Hanim Sen, et al.
Biophysical Reviews|February 2, 2018
Correction to: The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart diseaseC G Dos Remedios, S P Lal, A Li, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2014
Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trialHanim Sen, Ming Kai Lam, Kenneth Tandjung, et al.
European Heart Journal Open|November 13, 2025
Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-riskDaphne van Vliet, Eline H Ploumen, Tineke H Pinxterhuis, et al.
Journal of the American College of Cardiology|February 21, 2012
A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trialClemens von Birgelen, Mounir W Z Basalus, Kenneth Tandjung, et al.
Journal of the American College of Cardiology|April 23, 2013
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trialKenneth Tandjung, Hanim Sen, Ming Kai Lam, et al.
JACC. Cardiovascular Interventions|February 19, 2018
"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes StudyClemens von Birgelen, Marlies M Kok, Naveed Sattar, et al.
Biophysical Reviews|August 16, 2017
The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart diseaseC G Dos Remedios, S P Lal, A Li, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Journal of the American Heart Association|February 1, 2018
Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting StentsLiefke C van der Heijden, Marlies M Kok, Paolo Zocca, et al.
JAMA Cardiology|January 24, 2017
Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical TrialClemens von Birgelen, Liefke C van der Heijden, Mounir W Z Basalus, et al.
JACC. Cardiovascular Interventions|March 8, 2016
Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS TrialsMarlies M Kok, Liefke C van der Heijden, Hanim Sen, et al.
Biophysical Reviews|February 2, 2018
Correction to: The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart diseaseC G Dos Remedios, S P Lal, A Li, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|October 21, 2014
Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trialHanim Sen, Ming Kai Lam, Kenneth Tandjung, et al.
European Heart Journal Open|November 13, 2025
Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-riskDaphne van Vliet, Eline H Ploumen, Tineke H Pinxterhuis, et al.
Journal of the American College of Cardiology|February 21, 2012
A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trialClemens von Birgelen, Mounir W Z Basalus, Kenneth Tandjung, et al.
Journal of the American College of Cardiology|April 23, 2013
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trialKenneth Tandjung, Hanim Sen, Ming Kai Lam, et al.
JACC. Cardiovascular Interventions|February 19, 2018
"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes StudyClemens von Birgelen, Marlies M Kok, Naveed Sattar, et al.
Biophysical Reviews|August 16, 2017
The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart diseaseC G Dos Remedios, S P Lal, A Li, et al.
Pageof 9